作者
Joseph Nowatzke,Paul Guedeney,Nicholas Palaskas,Lorenz Lehmann,Stephane Ederhy,Han Zhu,Jennifer Cautela,Sanjeev Francis,Pierre-Yves Courand,Anita Deswal,Steven Ewer,Mandar Aras,Dimitri Arangalage,Kambiz Ghafourian,Charlotte Fenioux,Daniel Finke,Giovanni Peretto,Vlad Zaha,Osnat Itzhaki Ben Zadok,Kazuko Tajiri,Nausheen Akhter,Joshua Levenson,Lauren Baldassarre,John Power,Shi Huang,Jean-Philippe Collet,Javid Moslehi,Joe-Elie Salem,Nazanin Aghel,Joachim Alexandre,Kazutaka Aonuma,Aarti Asnani,Juliane Behling,Mehmet Bilen,Wendy Bottinor,Eve Cariou,Johnny Chahine,Weiting Chan,Aman Chauhan,Max Cohen,Shanthini Crusz,Susan Fernando,Roberta Florido,Mauro Frigeri,Satoshi Fukushima,Elizabeth Gaughan,Benjamin Geisler,Lauren Gilstrap,Christian Grohe,Avirup Guha,Manhal Habib,Eva Haegler-Laube,Andrew Haydon,Salim Hayek,Andrew Hughes,Rysk Imai,Yumi Katsume,Hideki Kimura,Lily Koo Lin,Carrie Lenneman,Daryl Leong,Vicky Makker,Nicolas Martinez-Calle,Melissa Moey,Masahiro Mohri,Ryota Morimoto,Yoshinobu Moritoki,Anna Narezkina,Martin Nicol,Ajay Nooka,Olusola Orimoloye,Milan Patel,Michal Perl,Nicolas Piriou,Jayant Raikhelkar,Yasmin Raza,Anjali Rao,Sunil Reddy,Nobuhiko Seki,Karl Stangl,Andrew Stewart,Bryan Stringer,Balaji Tamarappoo,Yuichi Tamura,Frank Thuny,Sean Tierney,Romain Tresorier,Waqas Ullah,Jean-Jacques von Hunolstein,Ellen Warner,Allison Weppler
摘要
Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis.An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram.Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p < 0.001) and was marginally associated with all-cause death (HR = 1.88, 95% CI, 0.98-3.61, p = 0.057).CAD may exist concomitantly with ICB-myocarditis and may portend a poorer outcome when revascularization is performed. This is potentially mediated through delayed diagnosis and treatment or more severe presentation of ICB-myocarditis.